- Home
- Publications
- Publication Search
- Publication Details
Title
RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 9, Pages 2183
Publisher
MDPI AG
Online
2019-05-07
DOI
10.3390/ijms20092183
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The RANK–RANKL axis: an opportunity for drug repurposing in cancer?
- (2019) S. Peters et al. Clinical & Translational Oncology
- The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review
- (2018) A.F. de Groot et al. CANCER TREATMENT REVIEWS
- Immune check-point in cervical cancer
- (2018) F. De Felice et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma
- (2018) Julien Faget et al. Journal of Thoracic Oncology
- Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma
- (2018) Muhammad Z. Afzal et al. MELANOMA RESEARCH
- RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
- (2018) Elizabeth Ahern et al. OncoImmunology
- Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer
- (2018) Bastien Nguyen et al. CANCER RESEARCH
- Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.
- (2018) Michael Gnant et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.
- (2018) Robert E. Coleman et al. JOURNAL OF CLINICAL ONCOLOGY
- Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
- (2018) Elizabeth Ahern et al. Nature Reviews Clinical Oncology
- 1385PDA randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial
- (2018) S Peters et al. ANNALS OF ONCOLOGY
- RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment
- (2018) Peter A. van Dam et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Quality indicators for the management of endometrial, cervical and ovarian cancer
- (2018) Anne-Sophie Bonte et al. EJSO
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
- (2017) Krishnansu S Tewari et al. LANCET
- RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease
- (2017) Frank Christoph et al. WORLD JOURNAL OF UROLOGY
- IL‑8 is upregulated in cervical cancer tissues and is associated with the proliferation and migration of HeLa cervical cancer cells
- (2017) Linlin Jia et al. Oncology Letters
- RANK and EGFR in invasive breast carcinoma
- (2017) Anastasios D. Papanastasiou et al. Cancer Genetics
- KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression
- (2017) Dong Ma et al. Scientific Reports
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- RANK-RANKL signalling in cancer
- (2016) N. Renema et al. BIOSCIENCE REPORTS
- RANK as a therapeutic target in cancer
- (2016) Eva González-Suárez et al. FEBS Journal
- The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses
- (2016) Lindsay K. Ward-Kavanagh et al. IMMUNITY
- Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma
- (2016) Mark J. Smyth et al. JOURNAL OF CLINICAL ONCOLOGY
- LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption
- (2016) Jian Luo et al. NATURE MEDICINE
- RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
- (2016) Emma Nolan et al. NATURE MEDICINE
- CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells
- (2016) Yao Liu et al. Oncotarget
- RANKL/RANK: from bone loss to the prevention of breast cancer
- (2016) Verena Sigl et al. Open Biology
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications
- (2015) Javier De Castro et al. Clinical Lung Cancer
- RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion
- (2015) WEN-QING SHANG et al. ONCOLOGY REPORTS
- In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment
- (2015) Pieter-Jan H. H. van Dam et al. Oncotarget
- Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion
- (2015) Stéphanie A Demoulin et al. OncoImmunology
- RANK-mediated signaling network and cancer metastasis
- (2014) Gina Chia-Yi Chu et al. CANCER AND METASTASIS REVIEWS
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- The Relationship between the Antitumor Effect of the IL-12 Gene Therapy and the Expression of Th1 Cytokines in an HPV16-Positive Murine Tumor Model
- (2014) Flor García Paz et al. MEDIATORS OF INFLAMMATION
- T5 Opg Regulates Pulmonary Arterial Smooth Muscle Cell Proliferation And The Expression Of Pah-associated Genes Via Fas
- (2014) S. Dawson et al. THORAX
- Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
- (2014) Matthew C. Walsh et al. Frontiers in Immunology
- Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis
- (2013) Pasquale Pellegrini et al. STEM CELLS
- A “vicious cycle” of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?
- (2013) Benjamin Joachim Schmiedel et al. OncoImmunology
- CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion
- (2012) Yasushi Sasaki et al. CANCER BIOLOGY & THERAPY
- RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
- (2012) M. Palafox et al. CANCER RESEARCH
- Identification of Novel Genes Selectively Expressed in the Follicle-Associated Epithelium from the Meta-Analysis of Transcriptomics Data from Multiple Mouse Cell and Tissue Populations
- (2012) A. Kobayashi et al. DNA RESEARCH
- Denosumab: mechanism of action and clinical outcomes
- (2012) D. A. Hanley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
- (2012) Giorgio Vittorio Scagliotti et al. Journal of Thoracic Oncology
- Targeted blockade of interleukin-8 abrogates its promotion of cervical cancer growth and metastasis
- (2012) Suhui Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- RANKL Expression Specifically Observed in Vivo Promotes Epithelial Mesenchymal Transition and Tumor Progression
- (2011) Tamaki Yamada et al. AMERICAN JOURNAL OF PATHOLOGY
- Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells
- (2011) Zhen-Ning Tang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
- (2011) Marc Baay et al. Clinical & Developmental Immunology
- Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
- (2011) W. C. Dougall CLINICAL CANCER RESEARCH
- Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas
- (2011) Taku Fujimura et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Breast-Cancer Adjuvant Therapy with Zoledronic Acid
- (2011) Robert E. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
- (2011) D. Castellano et al. ONCOLOGIST
- Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients
- (2011) Daniele Santini et al. PLoS One
- Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells
- (2010) H. Li et al. BLOOD
- RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
- (2010) Eva Gonzalez-Suarez et al. NATURE
- Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
- (2009) Penny E Reid et al. Molecular Cancer
- OPG, RANK and RANK ligand expression in thyroid lesions
- (2008) Marie-Françoise Heymann et al. REGULATORY PEPTIDES
- Regulatory T Cells: Mechanisms of Differentiation and Function
- (2007) Steven Z. Josefowicz et al. Annual Review of Immunology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More